Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(+)-Abscisic acid (HB4674)
Description:Phytohormone and endogenous lanthionine synthetase C-like 2 (LANCL2) ligand
Purity:>99%
Ac-Arg-Leu-Arg-AMC (HB3733)
Description:Fluorogenic tri-peptide substrate. Useful for measuring trypsin-like 20S proteasome peptidase activity.
Purity:>97%
Aftin-4 (HB3741)
Description:Roscovitine-related purine with no activity on CDKs. Roscovitine control. Increases Aβ42 production.
Purity:>98%
Aftin-5 (HB3742)
Description:Roscovitine-related purine with no activity on CDKs. Roscovitine control. Increases Aβ42 production.
Purity:>98%
- Description:
Ribosome-borne protein folding activity (RPFA) inhibitor
Purity:>99%
6-Aminophenanthridine (HB3730)
Description:Ribosome-borne protein folding activity (RPFA) inhibitor
Purity:>97%
β-Amyloid Peptide (1-42) (human) (HB9805)
Description:β-Amyloid (1-42) protein fragment. Implicated in Alzheimer's disease.